Redeyes main takeaway is that Nanologica adds support (pharma companies) in Drug Development and adds prospects in the preparative (Chromatography) business. The outlook remains positive, and Nanologica has increased its Silica production capacity substantially. Nanologica’s objective is to convert additional pipeline opportunities over the next 6 to 18 months.